Indications |
Oral Osteoarthritis Adult: 10 mg once daily.
Oral Rheumatoid arthritis Adult: 10 mg once daily.
Oral Dysmenorrhoea Adult: 20 mg bid. Hepatic impairment: Child-Pugh scale 7-9: Initiate with caution. Child-Pugh scale >10: Avoid. |
||||||||
Contraindications |
Hypersensitivity to sulfonamides, NSAIDs and other COX 2 inhibitors; asthma, urticaria; severe hepatic impairment; pregnancy (third trimester); lactation. Active GI bleed or ulceration, severe CHF, inflammatory bowel disease. | ||||||||
Warnings / Precautions |
Mild to moderate hepatic impairment; history of ulcer disease or GI bleeding; dehydration, hypertension, history of heart failure, left ventricular dysfunction, pre-existing oedema. Monitor Hb or haematocrit values for signs and symptoms of anaemia. | ||||||||
Adverse Reactions |
Hypertension, back pain, myalgia, peripheral oedema, influenza-like symptoms, dizziness, headache, abdominal fullness, abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, myalgia, sinusitis. Potentially Fatal: Toxic epidermal necrolysis, exfoliative dermatitis. |
||||||||
Drug Interactions |
Concomitant admin of aspirin may result in an increased risk of GI ulceration and complications. It decreases the antihypertensive effect of antihypertensives e.g. ACE inhibitors. It increases plasma conc of dextromethorphan. It significantly decreases lithium serum clearance and renal clearance. See Below for More valdecoxib Drug Interactions |
||||||||
Mechanism of Actions |
Valdecoxib acts by selectively inhibiting prostaglandin synthesis primarily by blocking cyclooxygenase (COX-2) enzyme. It was withdrawn worldwide in April 2005, following risk of serious skin reactions and cardiovascular side effects. Onset: 60 min. Absorption: Peak plasma concentrations after 2.25-3 hrs (oral). Distribution: Protein-binding: 98% Metabolism: Extensively hepatic. Excretion: Urine (as metabolites); 8-11 hrs (elimination half-life). |
||||||||
Administration |
May be taken with or without food. |
||||||||
Storage Conditions |
Oral: Store below 30°C. | ||||||||
ATC Classification |
M01AH03 - valdecoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs. | ||||||||
Storage |
Oral: Store below 30°C. | ||||||||
Available As |
|
Valdecoxib
Post Review about Valdecoxib Click here to cancel reply.
Valdecoxib Containing Brands
Valdecoxib is used in following diseases
Drug - Drug Interactions of Valdecoxib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.